利用1583例诊断性全外显子组测序数据重新用于临床药物基因组学
研究评估将现有诊断性全外显子组测序(WES)数据重新用于11个药物基因中42个变异panel的可行性,共纳入1583例儿童-父母三联体。成功提取39个变异结果,86%个体至少存在一个可操作表型,单倍型定相使1.5%的CYP2B6表型被纠正;结论认为WES数据可产出7个药物基因的有意义药物遗传学图谱。
要点
- 诊断性WES数据可重新用于药物基因组学分析,覆盖11个药物基因中42个变异panel。
- 39个变异可成功提取,CYP2C19、UGT1A1、CYP3A5三个变异及CYP2D6拷贝数无法提取。
- 86%个体至少存在一个可操作表型,单倍型定相使1.5%的CYP2B6表型被纠正。
核心结论
- 重新利用WES数据可为11个重要药物基因中的7个产出有意义的药物遗传学图谱,用于指导药物治疗。
研究设计与样本
- 研究利用现有诊断性全外显子组测序数据,纳入儿童-父母三联体共1583例个体,针对11个药物基因中42个变异panel进行分析。
主要发现
- 39个变异结果成功提取,3个变异(位于CYP2C19、UGT1A1和CYP3A5)及CYP2D6拷贝数无法提取信息。
- 86%的个体至少存在一个可操作表型。
- 单倍型定相与CYP2B6赋值相关,1.5%的表型在定相后被纠正。
临床怎么用
- 临床可考虑重新利用现有诊断性WES数据生成药物遗传学图谱,以指导相关药物治疗。
局限性
- 部分变异(CYP2C19、UGT1A1、CYP3A5的三个变异)及CYP2D6拷贝数无法从WES数据中提取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For ~ 80 drugs, widely recognized pharmacogenetics dosing guidelines are available. However, the use of these guidelines in clinical practice remains limited as only a fraction of patients is subjected to pharmacogenetic screening. We investigated the feasibility of repurposing whole exome sequencing (WES) data for a panel of 42 variants in 11 pharmacogenes to provide a pharmacogenomic profile. Existing diagnostic WES-data from child-parent trios totaling 1,583 individuals were used. Results were successfully extracted for 39 variants. No information could be extracted for three variants, located in CYP2C19, UGT1A1, and CYP3A5, and for CYP2D6 copy number. At least one actionable phenotype was present in 86% of the individuals. Haplotype phasing proved relevant for CYP2B6 assignments as 1.5% of the phenotypes were corrected after phasing. In conclusion, repurposing WES-data can yield meaningful pharmacogenetic profiles for 7 of 11 important pharmacogenes, which can be used to guide drug treatment.
引用
- van der Lee M, Allard WG, Bollen S, et al. Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. Clin Pharmacol Ther. 2019. PMID: 31594036. doi:10.1002/cpt.1665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。